PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · IEX Real-Time Price · USD
1.805
+0.075 (4.34%)
Apr 23, 2024, 4:00 PM EDT - Market closed
Company Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.
PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
PMV Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2013 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Dr. David H. Mack Ph.D. |
Contact Details
Address: One Research Way Princeton, New Jersey 08540 United States | |
| Phone | (609) 642-6664 |
| Website | pmvpharma.com |
Stock Details
| Ticker Symbol | PMVP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001699382 |
| CUSIP Number | 69353Y103 |
| ISIN Number | US69353Y1038 |
| Employer ID | 46-3218129 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Director and Member of Scientific Advisory Board |
| Dr. Thomas E. Shenk Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Michael Carulli | Chief Financial Officer |
| Robert Ticktin | General Counsel, Head of Operations and Company Secretary |
| Tim Smith | Senior Vice President and Head of Corporate Development and Investor Relations |
| Crystal Zuckerman | Vice President of Human Resources |
| Dr. Binh Vu Ph.D. | Senior Vice President of Drug Discovery and CMC |
| Dr. Deepika Jalota Pharm.D. | Chief Development Officer |
| Dr. Marc Fellous M.D. | Senior Vice President and Head of Clinical Development and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |